tirzepatide dual demonstrates cardiovascular protection in head-to-head trial with dulaglutide Tirzepatide: Dual GIP/GLP-1 Receptor Agonism

Each acts on a distinct node of the GHRHGHIGF-1 cascade because they engage different receptor targets upstream and downstream of the pituitary

Importantly, emerging evidence suggests that combination therapy with GLP-1 RAs and SGLT2is may provide synergistic benefits, producing greater reductions in body weight, glycated hemoglobin (HbA1c), and potentially liver-related endpoints compared with either therapy alone

Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al

With the advancement of research in the field of OC, the interest in using immunotherapy and bioengineering techniques in clinical settings is on the increase